ARCT Q4 2024 Earnings — Arcturus Therapeutics Holdings Inc. Revenue & Financial Results | Market Cap Arena

ARCTArcturus Therapeutics Holdings Inc.

$217M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$21M-16.3% YoY

Gross Profit

$21M100.0% margin

Operating Income

-$33M-159.0% margin

Net Income

-$30M-142.9% margin

EPS (Diluted)

$-1.11

QoQ Revenue Growth

-45.9%

Cash Flow

Operating Cash Flow

-$284,000

Free Cash Flow

-$284,000

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$344M

Total Liabilities

$103M

Stockholders' Equity

$241M

Cash & Equivalents

$237M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$21M	$25M	-16.3%
Gross Profit	$21M	$25M	-16.3%
Operating Income	-$33M	-$18M	-82.8%
Net Income	-$30M	-$12M	-156.3%

Revenue Segments

Collaboration Revenue

$21M92%

Grant

$2M8%